Stockreport

Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF on Roivant Sciences Ltd. (NASDAQ:ROIV) since the company announced positive results from its Phase 3 VALOR study testing Brepocitinib in dermatomyositis on September 17. [Read more]